Equities

Bioventix PLC

BVXP:LSE

Bioventix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,700.00
  • Today's Change-40.00 / -2.30%
  • Shares traded8.70k
  • 1 Year change-43.33%
  • Beta0.5828
Data delayed at least 20 minutes, as of Feb 06 2026 16:29 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Bioventix PLC's revenues fell -3.61% from 13.61m to 13.12m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 8.10m to 7.58m, a -6.33% decrease.
Gross margin90.86%
Net profit margin57.83%
Operating margin75.51%
Return on assets57.04%
Return on equity64.40%
Return on investment64.40%
More ▼

Cash flow in GBPView more

In 2025, cash reserves at Bioventix PLC fell by 919.65k. However, the company earned 7.03m from its operations for a Cash Flow Margin of 53.61%. In addition the company generated 173.16k cash from investing, though they paid out 8.12m more in financing than they received.
Cash flow per share1.46
Price/Cash flow per share11.84
Book value per share2.21
Tangible book value per share2.21
More ▼

Balance sheet in GBPView more

Bioventix PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio9.17
Quick ratio8.65
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in GBP

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -3.23% and -4.96%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)3.95%
Div growth rate (5 year)11.26%
Payout ratio (TTM)103.29%
EPS growth(5 years)1.04
EPS (TTM) vs
TTM 1 year ago		-5.65
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.